ERK1 Antibody (YA3921)
(Synonyms: ERK1; PRKM3; P44ERK1; P44MAPK; HS44KDAP; HUMKER1A; MGC20180)Based on 1 Customer Validation
ERK1 Antibody (YA3921) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to ERK1.
-
Host:
Mouse
-
Isotype:
IgG
-
Application:
WB, IHC-P, ICC/IF, FC, ELISA
-
Reactivity :
Human, Mouse, Rat, Monkey
-
Formulation:
Supplied in PBS with 0.05% sodium azide.
-
Conjugation:
Non-conjugated
Applications
| Application |
WB
WB: Western Blot
|
IHC-P
IHC-P: Immunohistochemistry-Paraffin
|
ICC/IF
ICC/IF: Immunocytochemistry/
Immunofluorescence |
FC
FC: Flow Cytometry
|
ELISA
ELISA: Enzyme Linked Immunosorbent Assay
|
|---|---|---|---|---|---|
| Dilution Ratio | 1:500-1:2000 | 1:200-1:1000 | 1:200-1:1000 | 1:200-1:400 | 1:10000 |
Product Details
ERK1 Antibody (YA3921) is a Mouse-derived and non-conjugated IgG1 monoclonal antibody, targeting to ERK1.
-
Host Mouse
-
Clonality Monoclonal
-
Species ReactivityHuman, Mouse, Rat, Monkey
-
Observed Molecular WeightObserved band size: 43 kDaNote: Due to possible protein modifications or aggregation, the molecular weight should be confirmed by actual measurement, and the predicted value is for reference only.
-
Calculated Molecular Weight Predicted band size: 43 kDa
Purified recombinant fragment of human MAPK3 aa 9-143.
affinity purified.
Non-conjugated
Unmodified
IgG
Product Properties
-
Appearance
Solution
-
Formulation
Supplied in PBS with 0.05% sodium azide.
-
Concentration
Batch-dependent, Please check the COA for the concentration of each lot. Check Lot Concentration
-
Storage & Stability
Stored at -20°C for 1 year. Avoid repeated freeze / thaw cycles.
-
Shipping
Shipping with blue ice.
Verification Images
-
Western blot analysis of extracts from Hela (lane 2(20μg), Hela (lane 3(40μg), using MAPK3 Antibody. Proteins were transferred to a PVDF membrane and blocked with 5% BSA in TBST for 2 hour at room temperature. The primary antibody and Loading control antibody (Beta Actin, HY-P80438, 1/3000) was used in 5% BSA in TBST at 4°C overnight. Goat Anti-Mouse/Rabbit IgG-HRP Secondary Antibody (HY-P8004/HY-P8001, 1/10,000) was used for 1 hour at room temperature.
-
Western blot analysis of extracts from PC-12(lane 1(40μg) ),NIH/3T3(lane 2(40μg) ),K562(lane 3(40μg) ),HEK293(lane 4(40μg) ),Raw246.7(lane 5(40μg) ),Jurkat(lane 6(40μg) )and Hela(lane 7(40μg) ) using MAPK3 antibody. Proteins were transferred to a NC membrane and blocked with 5% Skim milk in TBST for 2 hour at room temperature. The primary antibody ( 1/1000) and Loading control antibody (GAPDH,1/1000) was used in 5% Skim milk in TBST at 4°C overnight. Goat Anti-Mouse IgG-HRP Secondary Antibody (1/10,000) was used for 1 hour at room temperature.
-
Immunohistochemical analysis of paraffin-embedded human small intestine tissue using ERK1 Antibody (HY-P84224, 1/800). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded human kidney tissue using ERK1 Antibody (HY-P84224, 1/800). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded human testis tissue using ERK1 Antibody (HY-P84224, 1/800). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded human epididymis tissue using ERK1 Antibody (HY-P84224, 1/800). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded human ovary tissue using ERK1 Antibody (HY-P84224, 1/800). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Immunohistochemical analysis of paraffin-embedded human salivary gland tissue using ERK1 Antibody (HY-P84224, 1/800). The section was pretreated using heat mediated antigen retrieval with sodium citrate buffer (pH 6.0) for 8 minutes. The tissues were blocked with quick block buffer for 0.5 hours at room temperature, washed with PBS and PBST, and then incubated with the primary antibody overnight at 4℃. The detection was performed using an HRP conjugated compact polymer system. DAB was used as the chromogen. Tissues were counterstained with hematoxylin and mounted with DPX.
-
Flow cytometric analysis of 1X10^6 Hela cells labeling MAPK3 Antibody(red). Cells were fixed with 4% paraformaldehyde and permeabilised with 0.2% Triton X-100. Then stained with the primary antibody at 1/400 dilution overnight at 4℃.Alexa Fluor® 488 Goat Anti-mouse IgG H&L (invitrogen A11001) was used as the secondary antibody at 1/1,000 dilution for 45 minutes at room temperature. Mouse IgG Isotype Control (Invitrogen 14-4714-B2, blue) was used as the isotype control, cells without incubation with primary antibody were used as the unlabeled control (gray).
-
Immunofluorescence analysis of Hela cells labeling MAPK3 antibody at 1/50 dilution. Cells were fixed in 4% paraformaldehyde for 15 minutes at room temperature, permeabilized with 0.1% Triton X-100 in PBS for 15 minutes at room temperature, then blocked with 1% BSA in 10% negative goat serum for 1 hour at room temperature.Cells were then incubated with MAPK3 antibody at 1/50 dilution in 1% BSA in PBST overnight at 4 ℃. Alexa Fluor® 488 Goat Anti-mouse IgG H&L (invitrogen A11001, green) was used as the secondary antibody at 1/500 dilution. PBS instead of the primary antibody was used as the secondary antibody only control. The Nuclear counterstain was DAPI (Blue)
Background
-
Function
ERK1 (MAPK3) is a serine/threonine protein kinase that functions as an essential effector of the MAPK/ERK signaling cascade and transduces extracellular signals controlling cell proliferation, differentiation, migration, and survival[1][2]. Mechanistically, ERK1 operates downstream of the Ras/Raf/MEK pathway, where dual phosphorylation activates ERK signaling and enables phosphorylation of numerous substrates across multiple cellular compartments, thereby regulating gene expression and diverse physiological processes[2]. Because the MAPK/ERK pathway integrates growth factor, hormone, and stress-associated signals, dysregulated ERK signaling contributes to pathological conditions including cancer and other diseases characterized by aberrant cellular proliferation and survival signaling[1]. In experimental systems, ERK1 has been extensively investigated in developmental, vascular, and disease models to define its contribution to signal transduction and tissue responses[2][3]. Compared with the closely related isoform ERK2 (MAPK1), ERK1 exhibits highly conserved activation mechanisms, substrate recognition properties, and signaling outputs, and current evidence generally supports substantial functional redundancy between the two kinases[2]. Nevertheless, isoform-specific studies have identified distinct biological contexts in which ERK1 and ERK2 contribute differently to physiological processes, including vascular remodeling and arteriogenesis, indicating that isoform-dependent functions can emerge in specific cellular environments[3]. For experimental applications, pharmacological ERK1/2 inhibitors are widely used to interrogate terminal MAPK pathway signaling and to investigate mechanisms of therapeutic resistance associated with reactivation of ERK signaling downstream of RAF or MEK inhibition[1].
-
Subcellular Localization
Cytoplasm; Nucleus; Membrane, caveola; Cell junction, focal adhesion
-
Isoforms & Post-Translational Modification
P27361 has 3 isomers: P27361-1: 43136 Da (predicted); P27361-2: 38275 Da (predicted); P27361-3: 40088 Da (predicted).
Phosphorylated upon KIT and FLT3 signaling (By similarity). Dually phosphorylated on Thr-202 and Tyr-204, which activates the enzyme. Ligand-activated ALK induces tyrosine phosphorylation. Dephosphorylated by PTPRJ at Tyr-204;Ubiquitinated by TRIM15 via 'Lys-63'-linked ubiquitination; leading to activation. Deubiquitinated by CYLD -
Subunit
Binds both upstream activators and downstream substrates in multimolecular complexes. Found in a complex with at least BRAF, HRAS, MAP2K1/MEK1, MAPK3 and RGS14 (By similarity). Interacts with ADAM15, ARRB2, CANX, DAPK1 (via death domain), HSF4, IER3, MAP2K1/MEK1, MORG1, NISCH, and SGK1. Interacts with PEA15 and MKNK2 (By similarity). MKNK2 isoform 1 binding prevents from dephosphorylation and inactivation (By similarity). Interacts with TPR. Interacts with CDKN2AIP. Interacts with HSF1 (via D domain and preferentially with hyperphosphorylated form); this interaction occurs upon heat shock (PubMed:10747973). Interacts with CAVIN4 (By similarity). Interacts with GIT1; this interaction is necessary for MAPK3 localization to focal adhesions (By similarity). Interacts with ZNF263 (PubMed:32051553). Interacts with EBF4
-
SwissProt ID
-
Synonyms
ERK1; PRKM3; P44ERK1; P44MAPK; HS44KDAP; HUMKER1A; MGC20180
Documentation
-
Data Sheet (262 KB)
-
SDS (251 KB)
- English - EN (251 KB)
- Français - FR (251 KB)
- Deutsch - DE (251 KB)
- Norwegian - NO (251 KB)
- Español - ES (251 KB)
- Swedish - SV (251 KB)
- Italian - IT (251 KB)
- Korean - KR (251 KB)
- Portuguese - PT (251 KB)
-
User Guide for Antibodies (1077 KB)
[1]. Sah VK, et al. Advances in ERK1/2 inhibition: a medicinal chemistry perspective on structure and regulation. J Enzyme Inhib Med Chem. 2025 Dec;40(1):2555510. [Content Brief]
[2]. Buscà R, et al. ERK1 and ERK2 Map Kinases: Specific Roles or Functional Redundancy? Front Cell Dev Biol. 2016 Jun 8;4:53. [Content Brief]
[3]. Ricard N, et al. Isoform-Specific Roles of ERK1 and ERK2 in Arteriogenesis. Cells. 2019 Dec 21;9(1):38. [Content Brief]